Journal of Clinical Oncology, Vol 8, 1263-1268, Copyright © 1990 by American Society of Clinical Oncology
Hypersensitivity reactions from taxol
RB Weiss, RC Donehower, PH Wiernik, T Ohnuma, RJ Gralla, DL Trump, JR Baker Jr, DA Van Echo, DD Von Hoff and B Leyland-Jones
Department of Medicine, Walter Reed Army Medical Center, Washington, DC 20307.
Taxol is an antitumor agent in clinical trial that has been shown to have
activity against advanced ovarian carcinoma and melanoma. Hypersensitivity
reactions (HSRs) have been one of the toxicities observed with
administration of this drug. Of 301 patients treated, 32 patients have had
definite (27 patients) or possible (five patients) hypersensitivity
reactions to taxol. All but one patient had the reaction from the first or
second exposure to this agent. Reactions occurred at a variety of doses and
were characterized most frequently by dyspnea, hypotension, bronchospasm,
urticaria, and erythematous rashes. Thirteen (41%) patients had received
premedication designed to prevent such toxicity; nevertheless, they
sustained HSRs. Prolonging the drug infusion appears to have somewhat
reduced, but not obviated, the risk of HSRs. The cause (taxol itself or its
excipient Cremophor EL; Badische Anilin und Soda-Fabrik AG [BASF],
Ludwigshafen, Federal Republic of Germany) and the mechanism of these
reactions to taxol are unknown. We provide guidelines to prevent or
minimize such toxicity and treat reactions if they still occur.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
W. T. Lim, E. H. Tan, C. K. Toh, S. W. Hee, S. S. Leong, P. C. S. Ang, N. S. Wong, and B. Chowbay
Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol(R)-PM) in patients with solid tumors
Ann. Onc.,
July 24, 2009;
(2009)
mdp315v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. W. ten Bokkel Huinink, J. Sufliarsky, W. M. Smit, S. Spanik, M. Wagnerova, H. W. Hirte, S. Kaye, A. R. Johri, and A. M. Oza
Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study
J. Clin. Oncol.,
July 1, 2009;
27(19):
3097 - 3103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. SHIMADA, M. UEDA, H. JINNO, N. CHIBA, M. WADA, J. WATANABE, K. ISHIHARA, and Y. KITAGAWA
Development of Targeted Therapy with Paclitaxel Incorporated into EGF-conjugated Nanoparticles
Anticancer Res,
April 1, 2009;
29(4):
1009 - 1014.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Yerushalmi, M. R. Kramer, S. Rizel, A. Sulkes, K. Gelmon, T. Granot, V. Neiman, and S. M. Stemmer
Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study
Ann. Onc.,
March 1, 2009;
20(3):
437 - 440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Matsumura
Polymeric Micellar Delivery Systems in Oncology
Jpn. J. Clin. Oncol.,
December 1, 2008;
38(12):
793 - 802.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Fetterly, T. H. Grasela, J. W. Sherman, J. L. Dul, A. Grahn, D. Lecomte, J. Fiedler-Kelly, N. Damjanov, M. Fishman, M. P. Kane, et al.
Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia during Phase I Development of Liposome-Entrapped Paclitaxel
Clin. Cancer Res.,
September 15, 2008;
14(18):
5856 - 5863.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Banzato, S. Bobisse, M. Rondina, D. Renier, F. Bettella, G. Esposito, L. Quintieri, L. Melendez-Alafort, U. Mazzi, P. Zanovello, et al.
A Paclitaxel-Hyaluronan Bioconjugate Targeting Ovarian Cancer Affords a Potent In vivo Therapeutic Activity
Clin. Cancer Res.,
June 1, 2008;
14(11):
3598 - 3606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Hadaschik, H. Adomat, L. Fazli, Y. Fradet, R. J. Andersen, M. E. Gleave, and A. I. So
Intravesical Chemotherapy of High-Grade Bladder Cancer with HTI-286, A Synthetic Analogue of the Marine Sponge Product Hemiasterlin
Clin. Cancer Res.,
March 1, 2008;
14(5):
1510 - 1518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Hong, I.-H. Lee, Y. H. Kwak, Y. T. Park, H. C. Sung, I. C. Kwon, and H. Chung
Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation
Mol. Cancer Ther.,
December 1, 2007;
6(12):
3239 - 3247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Mita, A. J. Olszanski, R. C. Walovitch, R. P. Perez, K. MacKay, D. P. Tuck, C. Simmons, S. Hammond, M. M. Mita, M. Beeram, et al.
Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel
Clin. Cancer Res.,
June 1, 2007;
13(11):
3293 - 3301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Lenz
Management and Preparedness for Infusion and Hypersensitivity Reactions
Oncologist,
May 1, 2007;
12(5):
601 - 609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Donyai and G. J Sewell
Physical and chemical stability of paclitaxel infusions in different container types
Journal of Oncology Pharmacy Practice,
December 1, 2006;
12(4):
211 - 222.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. Boehmerle, U. Splittgerber, M. B. Lazarus, K. M. McKenzie, D. G. Johnston, D. J. Austin, and B. E. Ehrlich
Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism
PNAS,
November 28, 2006;
103(48):
18356 - 18361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Green, G. M. Manikhas, S. Orlov, B. Afanasyev, A. M. Makhson, P. Bhar, and M. J. Hawkins
Abraxane(R), a novel Cremophor(R)-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer
Ann. Onc.,
August 1, 2006;
17(8):
1263 - 1268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Hennenfent and R. Govindan
Novel formulations of taxanes: a review. Old wine in a new bottle?
Ann. Onc.,
May 1, 2006;
17(5):
735 - 749.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Desai, V. Trieu, Z. Yao, L. Louie, S. Ci, A. Yang, C. Tao, T. De, B. Beals, D. Dykes, et al.
Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel
Clin. Cancer Res.,
February 15, 2006;
12(4):
1317 - 1324.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. H. Rubin, J. Rothermel, F. Tesfaye, T. Chen, M. Hubert, Y.-Y. Ho, C.-H. Hsu, and A. M. Oza
Phase I Dose-Finding Study of Weekly Single-Agent Patupilone in Patients With Advanced Solid Tumors
J. Clin. Oncol.,
December 20, 2005;
23(36):
9120 - 9129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Nyman, K. J. Campbell, E. Hersh, K. Long, K. Richardson, V. Trieu, N. Desai, M. J. Hawkins, and D. D. Von Hoff
Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies
J. Clin. Oncol.,
November 1, 2005;
23(31):
7785 - 7793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, and J. O'Shaughnessy
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil-Based Paclitaxel in Women With Breast Cancer
J. Clin. Oncol.,
November 1, 2005;
23(31):
7794 - 7803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Harries, P. Ellis, and P. Harper
Nanoparticle Albumin-Bound Paclitaxel for Metastatic Breast Cancer
J. Clin. Oncol.,
November 1, 2005;
23(31):
7768 - 7771.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. K. Ibrahim, B. Samuels, R. Page, D. Doval, K. M. Patel, S.C. Rao, M. K. Nair, P. Bhar, N. Desai, and G. N. Hortobagyi
Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer
J. Clin. Oncol.,
September 1, 2005;
23(25):
6019 - 6026.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sparreboom, C. D. Scripture, V. Trieu, P. J. Williams, T. De, A. Yang, B. Beals, W. D. Figg, M. Hawkins, and N. Desai
Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)
Clin. Cancer Res.,
June 1, 2005;
11(11):
4136 - 4143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Sabbatini, C. Aghajanian, D. Dizon, S. Anderson, J. Dupont, J. V. Brown, W. A. Peters, A. Jacobs, A. Mehdi, S. Rivkin, et al.
Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
J. Clin. Oncol.,
November 15, 2004;
22(22):
4523 - 4531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Lu, T.-K. Yeh, M. Tsai, J. L.-S. Au, and M. G. Wientjes
Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy
Clin. Cancer Res.,
November 15, 2004;
10(22):
7677 - 7684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Rigas
Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review
Oncologist,
June 2, 2004;
9(suppl_2):
16 - 23.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.-Y. Kim, D.-W. Kim, J.-Y. Chung, S. G. Shin, S.-C. Kim, D. S. Heo, N. K. Kim, and Y.-J. Bang
Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies
Clin. Cancer Res.,
June 1, 2004;
10(11):
3708 - 3716.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-W. Kim, J.-S. Kwon, Y.-G. Kim, M. S. Kim, G.-S. Lee, T.-J. Youn, and M.-C. Cho
Novel Oral Formulation of Paclitaxel Inhibits Neointimal Hyperplasia in a Rat Carotid Artery Injury Model
Circulation,
March 30, 2004;
109(12):
1558 - 1563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Itoh, T. Sendo, T. Hirakawa, T. Goromaru, S. Takasaki, H. Yahata, H. Nakano, and R. Oishi
Role of Sensory Nerve Peptides Rather than Mast Cell Histamine in Paclitaxel Hypersensitivity
Am. J. Respir. Crit. Care Med.,
January 1, 2004;
169(1):
113 - 119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W. Tolcher, C. H. Takimoto, and E. K. Rowinsky
The Multifunctional, Multi-Institutional, and Sometimes Even Global Phase I Study: A Better Life for Phase I Evaluations or Just "Living Large"?
J. Clin. Oncol.,
November 1, 2002;
20(21):
4276 - 4278.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. D. Kolodgie, M. John, C. Khurana, A. Farb, P. S. Wilson, E. Acampado, N. Desai, P. Soon-Shiong, and R. Virmani
Sustained Reduction of In-Stent Neointimal Growth With the Use of a Novel Systemic Nanoparticle Paclitaxel
Circulation,
September 3, 2002;
106(10):
1195 - 1198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Plummer, M. Ghielmini, P. Calvert, M. Voi, J. Renard, G. Gallant, E. Gupta, H. Calvert, and C. Sessa
Phase I and Pharmacokinetic Study of the New Taxane Analog BMS-184476 Given Weekly in Patients with Advanced Malignancies
Clin. Cancer Res.,
September 1, 2002;
8(9):
2788 - 2797.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Denman, P. J. Gilbar, and E. A. Abdi
Hypersensitivity Reaction (HSR) to Docetaxel After a Previous HSR to Paclitaxel
J. Clin. Oncol.,
June 1, 2002;
20(11):
2760 - 2761.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Gilbar and A. Ridge
Dexamethasone prophylaxis for paclitaxel hypersensitivity
Journal of Oncology Pharmacy Practice,
June 1, 2002;
8(2-3):
81 - 87.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. K. Ibrahim, N. Desai, S. Legha, P. Soon-Shiong, R. L. Theriault, E. Rivera, B. Esmaeli, S. E. Ring, A. Bedikian, G. N. Hortobagyi, et al.
Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-free, Protein-stabilized, Nanoparticle Formulation of Paclitaxel
Clin. Cancer Res.,
May 1, 2002;
8(5):
1038 - 1044.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. V. Koshkina, J. C. Waldrep, L. E. Roberts, E. Golunski, S. Melton, and V. Knight
Paclitaxel Liposome Aerosol Treatment Induces Inhibition of Pulmonary Metastases in Murine Renal Carcinoma Model
Clin. Cancer Res.,
October 1, 2001;
7(10):
3258 - 3262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hidalgo, C. Aylesworth, L. A. Hammond, C. D. Britten, G. Weiss, J. Stephenson Jr, G. Schwartz, A. Patnaik, L. Smith, K. Molpus, et al.
Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel
J. Clin. Oncol.,
May 1, 2001;
19(9):
2493 - 2503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Kreklau, N. Liu, Z. Li, K. Cornetta, and L. C. Erickson
Comparison of Single- Versus Double-Bolus Treatments of O6-Benzylguanine for Depletion of O6-Methylguanine DNA Methyltransferase (MGMT) Activity in Vivo: Development of a Novel Fluorometric Oligonucleotide Assay for Measurement of Mgmt Activity
J. Pharmacol. Exp. Ther.,
April 12, 2001;
297(2):
524 - 530.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. Wong, A. N. Leung, G. J. Berry, K. A. Atkins, J. G. Montoya, S. J. Ruoss, and F. E. Stockdale
Paclitaxel-Induced Hypersensitivity Pneumonitis: Radiographic and CT Findings
Am. J. Roentgenol.,
March 1, 2001;
176(3):
718 - 720.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Bardelmeijer, J. H. Beijnen, K. R. Brouwer, H. Rosing, W. J. Nooijen, J. H. M. Schellens, and O. van Tellingen
Increased Oral Bioavailability of Paclitaxel by GF120918 in Mice through Selective Modulation of P-glycoprotein
Clin. Cancer Res.,
November 1, 2000;
6(11):
4416 - 4421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Malingre, J. M. M. Terwogt, J. H. Beijnen, H. Rosing, F. J. Koopman, O. van Tellingen, K. Duchin, W. W. T. B. Huinink, M. Swart, J. Lieverst, et al.
Phase I and Pharmacokinetic Study of Oral Paclitaxel
J. Clin. Oncol.,
June 12, 2000;
18(12):
2468 - 2475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Poujol, F. Pinguet, F. Bressole, M. Boustta, and M. Vert
Molecular Microencapsulation: Paclitaxel Formations in Aqueous Medium Using Hydrophobized Poly(L-Lysine Citramide Imide)
Journal of Bioactive and Compatible Polymers,
March 1, 2000;
15(2):
99 - 114.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Markman, A. Kennedy, K. Webster, B. Kulp, G. Peterson, and J. Belinson
Paclitaxel-Associated Hypersensitivity Reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center
J. Clin. Oncol.,
January 5, 2000;
18(1):
102 - 102.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. R N. Panday, M. T Huizing, O. van Tellingen, R. A Hakvoort, P. H B Willemse, A. De Graeff, J. B Vermorken, and J. H Beijnen
Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving paclitaxel
Journal of Oncology Pharmacy Practice,
June 1, 1999;
5(2):
83 - 86.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Markman, A. Kennedy, K. Webster, P. Elson, G. Peterson, B. Kulp, and J. Belinson
Clinical Features of Hypersensitivity Reactions to Carboplatin
J. Clin. Oncol.,
April 1, 1999;
17(4):
1141 - 1141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Li, J. E. Price, L. Milas, N. R. Hunter, S. Ke, D.-F. Yu, C. Charnsangavej, and S. Wallace
Antitumor Activity of Poly(L-glutamic acid)-Paclitaxel on Syngeneic and Xenografted Tumors
Clin. Cancer Res.,
April 1, 1999;
5(4):
891 - 897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. K Webster, D. M Woodcock, D. Rischin, and M. J Millward
Review : Cremophor: Pharmacological activity of an "inert" solubiliser
Journal of Oncology Pharmacy Practice,
December 1, 1997;
3(4):
186 - 192.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y. F. Lam, C. J. Chan, and J. G Kuhn
Review : Pharmacokinetics and pharmacodynamics of the taxanes
Journal of Oncology Pharmacy Practice,
June 1, 1997;
3(2):
76 - 93.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Nakashima, O. Keller, S. Speck, and K. Swenerton
Significant hypersensitivity with paclitaxel managed by a 50 hour infusion
Journal of Oncology Pharmacy Practice,
June 1, 1995;
1(1):
47 - 50.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. K. Rowinsky and R. C. Donehower
Paclitaxel (Taxol)
N. Engl. J. Med.,
April 13, 1995;
332(15):
1004 - 1014.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Cannistra
Cancer of the Ovary
N. Engl. J. Med.,
November 18, 1993;
329(21):
1550 - 1559.
[Full Text]
|
|
|
|
